-
Je něco špatně v tomto záznamu ?
Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas
I. Hamova, M. Maco, A. Tkachenko, K. Kupcova, A. Velasova, M. Trneny, H. Mocikova, O. Havranek
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- cirkulující nádorová DNA * krev genetika MeSH
- difúzní velkobuněčný B-lymfom * diagnóza genetika terapie krev MeSH
- folikulární lymfom * diagnóza genetika terapie krev MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery * krev genetika MeSH
- prognóza MeSH
- tekutá biopsie metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Pathogenesis of large B-cell lymphomas (LBCL) and follicular lymphomas (FL) is a multistep process associated with the development of diverse DNA alterations and consequent deregulation of critical cellular processes. Detection of tumor-associated mutations within non-tumor compartments (mainly plasma) is the basis of the 'liquid biopsy' concept. Apart from tumor mutational profiling, quantitative analysis of circulating tumor DNA (ctDNA) allows longitudinal assessment of tumor burden. ctDNA-based technologies provide a new tool for tumor diagnostics and treatment personalization. AREAS COVERED: Our review provides a comprehensive overview and summary of available ctDNA studies in LBCL and FL. The accuracy of ctDNA-based detection of lymphoma-associated DNA alterations is correlated to known LBCL and FL molecular landscape. Additionally, we summarized available evidence that supports and justifies the clinical use of ctDNA for lymphoma risk stratification, treatment response evaluation, and treatment response-adapted therapy. Lastly, we discuss other clinically important ctDNA applications: monitoring of lymphoma clonal evolution within resistance and/or relapse development and utilization of ctDNA for diagnostics in non-blood fluids and compartments (e.g. cerebrospinal fluid in primary CNS lymphomas). EXPERT OPINION: Despite certain challenges, including methodological standardization, ctDNA holds promise to soon become an integral part of lymphoma diagnostics and treatment management.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015450
- 003
- CZ-PrNML
- 005
- 20250731091005.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14737159.2025.2500659 $2 doi
- 035 __
- $a (PubMed)40326242
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hamova, Iva $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 245 10
- $a Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas / $c I. Hamova, M. Maco, A. Tkachenko, K. Kupcova, A. Velasova, M. Trneny, H. Mocikova, O. Havranek
- 520 9_
- $a INTRODUCTION: Pathogenesis of large B-cell lymphomas (LBCL) and follicular lymphomas (FL) is a multistep process associated with the development of diverse DNA alterations and consequent deregulation of critical cellular processes. Detection of tumor-associated mutations within non-tumor compartments (mainly plasma) is the basis of the 'liquid biopsy' concept. Apart from tumor mutational profiling, quantitative analysis of circulating tumor DNA (ctDNA) allows longitudinal assessment of tumor burden. ctDNA-based technologies provide a new tool for tumor diagnostics and treatment personalization. AREAS COVERED: Our review provides a comprehensive overview and summary of available ctDNA studies in LBCL and FL. The accuracy of ctDNA-based detection of lymphoma-associated DNA alterations is correlated to known LBCL and FL molecular landscape. Additionally, we summarized available evidence that supports and justifies the clinical use of ctDNA for lymphoma risk stratification, treatment response evaluation, and treatment response-adapted therapy. Lastly, we discuss other clinically important ctDNA applications: monitoring of lymphoma clonal evolution within resistance and/or relapse development and utilization of ctDNA for diagnostics in non-blood fluids and compartments (e.g. cerebrospinal fluid in primary CNS lymphomas). EXPERT OPINION: Despite certain challenges, including methodological standardization, ctDNA holds promise to soon become an integral part of lymphoma diagnostics and treatment management.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cirkulující nádorová DNA $x krev $x genetika $7 D000074141
- 650 12
- $a folikulární lymfom $x diagnóza $x genetika $x terapie $x krev $7 D008224
- 650 12
- $a nádorové biomarkery $x krev $x genetika $7 D014408
- 650 12
- $a difúzní velkobuněčný B-lymfom $x diagnóza $x genetika $x terapie $x krev $7 D016403
- 650 _2
- $a tekutá biopsie $x metody $7 D000073890
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mutace $7 D009154
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Maco, Maria $u Department of Haematology, Fakultni nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Tkachenko, Anton $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kupcova, Kristyna $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Velasova, Adriana $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Trneny, Marek $u First Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Mocikova, Heidi $u Department of Haematology, Fakultni nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Havranek, Ondrej $u Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00174421 $t Expert review of molecular diagnostics $x 1744-8352 $g Roč. 25, č. 6 (2025), s. 275-295
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40326242 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091000 $b ABA008
- 999 __
- $a ok $b bmc $g 2366344 $s 1252575
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 25 $c 6 $d 275-295 $e 20250522 $i 1744-8352 $m Expert review of molecular diagnostics $n Expert Rev Mol Diagn $x MED00174421
- LZP __
- $a Pubmed-20250708
